Oscar Health (NYSE:OSCR) Posts Quarterly Earnings Results, Misses Expectations By $0.32 EPS

Oscar Health (NYSE:OSCR) announced its quarterly earnings results on Tuesday. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.32), FiscalAI reports. The firm had revenue of $2.76 billion for the quarter, compared to analyst estimates of $3.12 billion. Oscar Health had a negative net margin of 2.16% and a negative return on equity of 21.50%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.62) EPS.

Here are the key takeaways from Oscar Health’s conference call:

• Oscar delivered record open enrollment and rapid membership growth — 3.4 million enrolled as of Feb 1, 2026 and management expects ~3.0 million paid members (≈58% YoY paid-member growth) with market share up to 30%.
• Despite revenue of $11.7B (+28% YoY), Oscar reported a 2025 operating loss (~$396M) and net loss (~$443M), driven largely by higher market morbidity and a $275M Q4 risk-adjustment true-up.
• Management expects a meaningful financial turnaround in 2026 with guidance of $18.7–$19.0B revenue, an MLR of 82.4%–83.4%, SG&A of ~15.8%–16.3%, and projected earnings from operations of $250–$450M (returning to profitability).
• Operational levers underpinning the outlook include AI-driven efficiency gains (admin costs down ~160 bps; Oswell answers 86% of member questions), new lifestyle and ICHRA products, and expanded broker distribution—cited as durable growth and margin drivers.

Oscar Health Trading Up 1.3%

NYSE:OSCR traded up $0.17 during mid-day trading on Tuesday, hitting $12.83. 25,811,274 shares of the company’s stock were exchanged, compared to its average volume of 9,114,921. Oscar Health has a fifty-two week low of $11.20 and a fifty-two week high of $23.80. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $3.40 billion, a P/E ratio of -11.46 and a beta of 1.90. The company has a 50 day simple moving average of $15.52 and a 200-day simple moving average of $16.75.

Wall Street Analyst Weigh In

OSCR has been the subject of several research reports. Wall Street Zen cut Oscar Health from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. UBS Group upgraded shares of Oscar Health from a “sell” rating to a “neutral” rating and raised their price target for the stock from $12.00 to $17.00 in a research report on Friday, January 9th. Barclays set a $18.00 price target on shares of Oscar Health and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Wells Fargo & Company reduced their price target on shares of Oscar Health from $14.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, November 13th. Finally, Stephens initiated coverage on shares of Oscar Health in a research note on Thursday, December 11th. They set an “equal weight” rating and a $17.00 price target on the stock. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $17.00.

Insider Transactions at Oscar Health

In related news, insider Janet Liang sold 7,338 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $16.59, for a total value of $121,737.42. Following the completion of the sale, the insider directly owned 172,527 shares of the company’s stock, valued at approximately $2,862,222.93. This represents a 4.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Adam Mcananey sold 1,852 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $16.59, for a total value of $30,724.68. Following the transaction, the insider owned 179,241 shares of the company’s stock, valued at $2,973,608.19. The trade was a 1.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 197,125 shares of company stock worth $3,265,300 in the last three months. Insiders own 25.11% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Strs Ohio acquired a new position in Oscar Health during the 1st quarter worth approximately $30,000. Jones Financial Companies Lllp grew its position in Oscar Health by 7,473.3% in the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock worth $30,000 after buying an additional 2,242 shares during the last quarter. Quarry LP raised its position in Oscar Health by 439.8% during the third quarter. Quarry LP now owns 1,803 shares of the company’s stock valued at $34,000 after buying an additional 1,469 shares during the period. Binnacle Investments Inc acquired a new stake in Oscar Health in the second quarter valued at approximately $75,000. Finally, National Bank of Canada FI acquired a new stake in shares of Oscar Health in the third quarter valued at about $81,000. 75.70% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Company pushed a bullish 2026 message — management signaled a path back to profitability in 2026 and framed the quarter as a setup year, which reassured investors that losses should narrow next year. Oscar Health Bets On 2026 Profit Turnaround After Tough 2025
• Positive Sentiment: Revenue grew year-over-year (about +17%), showing top-line expansion and enrollee growth despite cost pressures — a constructive element for longer-term revenue trajectory. Q4 results / press release
• Neutral Sentiment: Full earnings release and call transcript are available for detail — analysts and investors will parse guidance assumptions and medical cost trends on the conference call. Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025
• Neutral Sentiment: Earnings call transcripts and coverage (Seeking Alpha / Yahoo) provide management commentary on utilization, pricing and reserves that will drive near-term performance. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: EPS declined to a ($1.24) loss (vs. est. around ($0.84)) and reported revenue came in below consensus — these misses pressured sentiment and underscore persistent margin challenges. OSCR Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Medical utilization remains elevated, widening the loss and keeping margins negative — WSJ and other coverage highlight that higher claims drove the weaker earnings profile. Oscar Health Revenue Rises, Eyes Profitability This Year

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.